leflunomide has been researched along with Bone Loss, Osteoclastic in 3 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Leflunomide is a disease-modifying antirheumatic drug that inhibits paw swelling and joint destruction in type II collagen-induced arthritis in mice and it also delays disease progression in patients with rheumatoid arthritis (RA), through inhibiting proliferation and cytokine production of T cells, via the blocking of de-novo pyrimidine biosynthesis by its active metabolite, A771726." | 1.32 | The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. ( Arai, Y; Hakeda, Y; Kaneda, T; Kobayashi, Y; Kumegawa, M; Sato, T; Shin, K; Ueyama, S; Yoshida, Y, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, C | 1 |
| Li, J | 1 |
| Lu, C | 1 |
| Xie, D | 1 |
| Liu, J | 1 |
| Zhong, C | 1 |
| Wu, X | 1 |
| Dai, R | 1 |
| Zhang, H | 1 |
| Guan, D | 1 |
| Guo, B | 1 |
| He, B | 1 |
| Li, F | 1 |
| He, X | 1 |
| Zhang, W | 1 |
| Zhang, BT | 1 |
| Zhang, G | 1 |
| Lu, A | 1 |
| Kobayashi, Y | 1 |
| Ueyama, S | 1 |
| Arai, Y | 1 |
| Yoshida, Y | 1 |
| Kaneda, T | 1 |
| Sato, T | 1 |
| Shin, K | 1 |
| Kumegawa, M | 1 |
| Hakeda, Y | 1 |
| Lequerré, T | 1 |
| Jouen, F | 1 |
| Brazier, M | 1 |
| Clayssens, S | 1 |
| Klemmer, N | 1 |
| Ménard, JF | 1 |
| Mejjad, O | 1 |
| Daragon, A | 1 |
| Tron, F | 1 |
| Le Loët, X | 1 |
| Vittecoq, O | 1 |
3 other studies available for leflunomide and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis.
Topics: Acriflavine; Adult; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Aryl Hydrocarbon Recept | 2019 |
The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Topics: Aniline Compounds; Animals; Binding Sites; Bone Resorption; Carrier Proteins; Cell Differentiation; | 2004 |
Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Autoantibodies; Bi | 2007 |